The EMPA-REG OUTCOME trial was the first to demonstrate the beneficialeffects of SGLT2 inhibitors in HF, showing a significant reduction in HFhospitalizations among diabetic patients taking an SGLT2 inhibitor [70]. Here, SLC5A2 is linked to hydrops fetalis.